• 03 Jun 2024
• Admin
• News Article

US FDA Approves Moderna’s an mRNA Respiratory Syncytial Virus Vaccine, mRESVIAa

Overview

Moderna, Inc. announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.

Words from CEO: Moderna

• "The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform," said Stéphane Bancel, chief executive officer of Moderna. 
• "mRESVIA protects older adults from the severe outcomes of RSV infection, and it is the only RSV vaccine available in a pre-filled syringe designed to maximize ease of administration, saving vaccinators' time and reducing the risk of administrative errors. This approval is also the first time an mRNA vaccine has been approved for a disease other than Covid-19. With mRESVIA, we continue to deliver for patients by addressing global public health threats related to infectious diseases."

About RSV

• RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia that causes a particularly large burden of disease in infants and older adults. 
• Each year in the US, approximately 60,000-160,000 older adults are hospitalized and 6,000-10,000 die due to RSV infection.

Phase 3 Clinical Trial ConquerRSV

• The FDA's approval of mRESVIA is based on positive data from the phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries. 
• The primary analysis with 3.7 months of median follow-up found a vaccine efficacy against RSV lower respiratory tract disease (LRTD) of 83.7% (95.88% CI 66.0%, 92.2%). 
• These results were published in The New England Journal of Medicine. A follow-up analysis of the primary endpoint was performed during FDA review, including cases that started before the primary analysis cut-off date but were not confirmed until afterward. 
• The results were consistent with the primary analysis [VE 78.7% (CI 62.9%, 87.8%)] and were included in the US package insert. 
• An additional longer-term analysis showed continued protection against RSV LRTD over 8.6 months median follow-up.

Safety Concerns:- 

No serious safety concerns were identified in the phase 3 trial. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia.

Moderna expects to have mRESVIA available for eligible populations in the US by the 2024/2025 respiratory virus season.

Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world.

mRESVIA

• mRESVIA is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. 
• The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. 
• The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. 
• The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna Covid-19 vaccines.

Moderna

• Moderna is a leader in the creation of the field of mRNA medicine. 
• Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone.